anti-HER2 225Ac-PRIT

anti-HER2 225Ac-PRIT is an experimental pre-targeted radioimmunotherapy (PRIT) system designed for the treatment of HER2-positive malignancies, specifically epithelial ovarian cancer and peritoneal carcinomatosis. Developed by researchers at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, the therapy utilizes a multi-step delivery mechanism to maximize tumor radiation dose while minimizing systemic toxicity. The system typically involves the administration of a pre-targeting agent—such as a bispecific antibody or a Self-Assembling DisAssembling Antibody (SADA)—that binds to the Human Epidermal Growth Factor Receptor 2 (HER2) on cancer cells. After the pre-targeting agent has cleared from the circulation, a small molecule chelate (DOTA) carrying the alpha-emitting radioisotope Actinium-225 (225Ac) is administered. This radioligand rapidly and specifically binds to the pre-targeted agent at the tumor site, delivering high-linear energy transfer (LET) alpha radiation that causes lethal double-strand DNA breaks in malignant cells. Preclinical studies have demonstrated high curative potential in advanced ovarian cancer models with a favorable safety profile.

Other names

225Ac-DOTA-PRITHER2-targeted alpha-PRITHER-2-targeted alpha-PRITHER 2-targeted alpha-PRITanti-HER2 225Ac-DOTA-PRITanti-HER-2 225Ac-DOTA-PRITanti-HER 2 225Ac-DOTA-PRIT